Perimenopause treatment goes wrong when every symptom is treated like the same hormone problem.
Hot flashes are one category. Heavy bleeding is another. Vaginal dryness is another. Sleep, mood, acne, hair shedding, weight, migraine, libido, and contraception all change the decision.
That matters because "wait it out" can be a long plan. In Study of Women's Health Across the Nation, frequent vasomotor symptoms lasted a median 7.4 years overall and persisted a median 4.5 years after the final menstrual period among women with an observable final period. [5]
The strongest treatment plan starts by naming the job and checking what must be ruled out first.
Decision table: match the symptom to the treatment category
| Main problem | Common treatment category | What must be checked first | Useful next question |
|---|---|---|---|
| Hot flashes or night sweats | Hormone therapy if appropriate; nonhormonal options if not | Contraindications, age/timing, uterus status, bleeding pattern, and medication interactions | Is this frequent enough to treat now rather than waiting years? |
| Vaginal dryness, painful sex, recurrent urinary symptoms | Local vaginal therapies or genitourinary syndrome review | Bleeding, infection symptoms, pelvic pain, and breast/cancer history complexity | Is the problem local, systemic, or both? |
| Heavy or irregular bleeding | Bleeding evaluation and cycle-control discussion | Pregnancy possibility, anemia, fibroids/polyps, medications, and endometrial risk | Does bleeding need evaluation before symptom treatment? |
| Sleep disruption | Treat night sweats if present; evaluate insomnia separately | Sleep apnea, anxiety, alcohol, medications, restless legs, thyroid disease, and night sweats | Is sleep broken by heat, insomnia, breathing, mood, or medication? |
| Mood changes | Mental health assessment plus symptom-trigger review | Depression, anxiety, suicidality, medication effects, thyroid disease, and safety concerns | Is this a menopause-associated symptom, a mood disorder, or both? |
| Acne or hair shedding | Dermatology or hair-loss pathway | Pattern, labs when appropriate, medication triggers, androgen signs, and scalp disease | Is this androgen-pattern, shedding, inflammation, or medication-related? |
| Weight/body composition | Metabolic and strength-preserving plan | A three-month blood sugar marker, blood pressure, lipids, sleep, medications, muscle, bone risk, and waist pattern | Is the plan protecting muscle and cardiometabolic risk, not just weight? |
| Low sexual desire | hypoactive sexual desire disorder/genitourinary syndrome of menopause/relationship/medication review; testosterone only for selected cases | Pain, dryness, mood, medication, relationship context, and hormone-therapy response | Is desire low because of pain, dryness, mood, sleep, or hypoactive sexual desire disorder? |
Where hormone therapy fits
The 2022 North American Menopause Society position statement says hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause. It can also prevent bone loss and fracture in selected patients. [1]
The benefit-risk profile is generally more favorable for healthy symptomatic women who are younger than 60. The same is true for women within 10 years of menopause onset. Later initiation changes the risk conversation. [1]
That does not mean everyone in perimenopause should take hormone therapy.
It means hormone therapy belongs in a screened decision. The clinician needs to know uterus status, contraception need, and whether bleeding needs evaluation first.
Contraindications also matter. These can include breast cancer history complexity, unexplained bleeding, clot, stroke, coronary disease, active liver disease, or other risk factors.
In perimenopause, the regimen can be harder than in postmenopause because bleeding may still happen and pregnancy risk may not be zero. A person with a uterus requires an endometrial-protection strategy if systemic estrogen is used. A person who still needs contraception may need a different plan than a person who has already reached menopause.
Where nonhormonal options fit
The 2023 nonhormone therapy position statement from The Menopause Society supports several nonhormonal options for vasomotor symptoms. Options include certain selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, gabapentin, fezolinetant, and oxybutynin. Elinzanetant (Lynkuet), approved later, is another FDA-labeled nonhormonal prescription option for moderate to severe vasomotor symptoms due to menopause. It blocks both NK1 and NK3 receptors, while fezolinetant blocks NK3. Each option has its own side-effect, interaction, and monitoring profile. [2] [7] [8]
This is useful when estrogen is not wanted, not appropriate, or not enough. It is not a reason to treat every symptom with the same nonhormonal medication.
| Option | When it may fit | When it needs caution |
|---|---|---|
| Hormone therapy | Bothersome hot flashes or night sweats in an appropriate candidate, especially younger than 60 or within 10 years of menopause onset. [1] | Unexplained bleeding, breast cancer complexity, clot/stroke/coronary history, active liver disease, or other individualized contraindications. |
| Menopause-specific cognitive behavioral therapy | Vasomotor symptoms, sleep problems, or depressive symptoms when skills-based support is desired or hormone replacement therapy is not preferred. [2] [3] | It is not a rapid rescue for severe night sweats, and it does not evaluate bleeding. |
| selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor | Vasomotor symptoms when estrogen is unsuitable or not wanted; may also fit mood context in selected cases. [2] | Drug interactions, sexual side effects, sleep effects, blood pressure for some agents, and withdrawal/taper planning. |
| Gabapentin | Nighttime symptoms when sleep disruption is prominent and sedation may be acceptable. [2] | Dizziness, sedation, falls, kidney dosing, and next-day fogginess. |
| Fezolinetant | Moderate-to-severe vasomotor symptoms when hormone replacement therapy is unsuitable. [2] [7] | Requires baseline liver tests and follow-up tests monthly for 3 months, then at months 6 and 9; CYP1A2 inhibitors, cirrhosis, and severe renal impairment are contraindication issues. [7] |
| Elinzanetant (Lynkuet) | Moderate-to-severe vasomotor symptoms when a nonhormonal neurokinin-pathway option is preferred. [8] | Requires baseline liver tests and repeat transaminases at 3 months. Pregnancy is contraindicated; sedation, seizure history, CYP3A4 interactions, and moderate-to-severe liver impairment need review. [8] |
| Oxybutynin | Vasomotor symptoms in selected cases when anticholinergic risk is acceptable. [2] | Dry mouth, constipation, urinary retention, cognition concerns, glaucoma risk, and medication burden. |
| Vaginal estrogen or local genitourinary syndrome of menopause options | Vaginal dryness, painful sex, recurrent urinary symptoms, or genitourinary syndrome of menopause-dominant symptoms. [1] [3] | Cancer-history complexity or unexplained bleeding should be reviewed rather than self-managed. |
Perimenopause-specific wrinkle: contraception
Perimenopause is not menopause. Pregnancy risk declines, but it is not zero until menopause is confirmed or another reliable standard is met.
On treatment choices after 40, American College of Obstetricians and Gynecologists guidance says hormone testing usually is not needed when age, symptoms, and period changes fit perimenopause. [3]
This matters because some hormone regimens treat symptoms but do not provide contraception. Hormonal contraception can also hide the bleeding pattern that would otherwise help stage the transition.
There is also perimenopause-specific research. One trial studied oral micronized progesterone for perimenopausal night sweats and hot flushes. That is a narrower question than "all hormones for all symptoms." [4]
That progesterone trial randomized 189 perimenopausal women aged 35-58 to 300 mg oral micronized progesterone at bedtime or placebo. The third-month vasomotor symptom score difference did not reach statistical significance, but perceived night sweats and sleep quality improved. [4] The practical point is not that progesterone solves perimenopause. It is that each hormone question has a specific population, dose, symptom target, and evidence limit.
Red flags before choosing treatment
| Situation | Why treatment should wait | Safer next step |
|---|---|---|
| Bleeding after menopause, bleeding after sex, or bleeding between periods | American College of Obstetricians and Gynecologists lists these as abnormal bleeding patterns, and abnormal bleeding can reflect polyps, fibroids, ovulation problems, medications, endometrial hyperplasia, or cancer. [6] | Bleeding-focused evaluation before assuming this is just perimenopause. |
| Very heavy bleeding, symptoms of anemia, or acute heavy bleeding | American College of Obstetricians and Gynecologists notes acute heavy bleeding may need treatment right away before cause-finding continues. [6] | Same-day or urgent care depending on severity. |
| Symptoms before age 40 | American College of Obstetricians and Gynecologists guidance says bleeding changes before 40 may need hormone testing to assess premature or early menopause. [3] | Do not manage as routine perimenopause without assessment. |
| New chest pain, neurologic symptoms, severe headache, shortness of breath, or leg swelling | These may change hormone-safety decisions or require urgent evaluation. | Urgent or emergency care based on severity. |
| Severe depression, suicidal thoughts, panic, or disabling anxiety | Menopause can overlap with mood symptoms, but safety comes first. | Same-day mental health or urgent review if safety is a concern. |
| Breast cancer, high breast-cancer risk, clot, stroke, coronary disease, active liver disease, or complex migraine history | These can alter whether systemic hormone therapy or other medications fit. | A clinician with menopause expertise may be needed. |
Who it fits, and who should avoid rushing
A treatment-first visit may fit when symptoms are frequent, sleep-disrupting, or interfering with work, sex, exercise, or daily life, and when bleeding patterns are understood enough to choose safely.
A review-first visit is usually the better fit when the main problem is heavy bleeding, bleeding after sex, very long gaps followed by flooding, severe mood symptoms, new migraine complexity, chest pain, neurologic symptoms, or a history that could make estrogen or other medications unsafe.
This distinction matters because the useful next step is not "buy hormones." It is "match the symptom to the screened care path." A woman with night sweats and no contraindication may need a different conversation than a woman with heavy bleeding, a uterus, migraine with aura, or cancer-history complexity.
A structured assessment should sort the symptom target, bleeding pattern, uterus status, contraception need, contraindications, treatment preferences, and follow-up plan before a prescription decision. That is especially important when multiple symptoms point in different directions.
What to ask a clinician
Ask:
- Which symptom are we treating first?
- Does my bleeding pattern need evaluation before treatment?
- Do I still need contraception?
- Do I have a uterus, and does that change the hormone plan?
- What would make hormone therapy, fezolinetant, elinzanetant, a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor, gabapentin, or another option a bad fit?
- If I use fezolinetant or elinzanetant, which liver tests and medication-interaction checks does that drug's current label require?
- If I use a local vaginal therapy, what symptoms should improve and what bleeding would still need evaluation?
- What should improve, by when should we reassess, and what is the plan if symptoms return when treatment stops?
Bottom line
Perimenopause treatment is not one decision.
It is a set of smaller decisions: symptom target, safety screen, bleeding review, contraception need, uterus status, medication fit, and follow-up plan.
Related reading: hormone replacement therapy contraindications after menopause, fezolinetant vs hormone replacement therapy, perimenopause bleeding changes, and perimenopause supplements.
References
[1] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[2] New Collective Author. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi:10.1097/gme.0000000000002200 https://pubmed.ncbi.nlm.nih.gov/37252752/
[3] ACOG. Do I need to have testing of my hormone levels during perimenopause?. https://www.acog.org/womens-health/experts-and-stories/ask-acog/do-i-need-to-have-testing-of-my-hormone-levels-during-perimenopause
[4] Prior JC, Cameron A, Fung M, et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial. Sci Rep. 2023;13(1):9082. doi:10.1038/s41598-023-35826-w https://pubmed.ncbi.nlm.nih.gov/37277418/
[5] Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-9. doi:10.1001/jamainternmed.2014.8063 https://pubmed.ncbi.nlm.nih.gov/25686030/
[6] ACOG. Abnormal Uterine Bleeding. https://www.acog.org/womens-health/faqs/abnormal-uterine-bleeding
[7] DailyMed. VEOZAH fezolinetant prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cae9f798-24f9-4580-a4fc-e6c710cbda3c
[8] DailyMed. LYNKUET (elinzanetant) prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f42884ff-7dff-419c-8a0c-affe2ed73818